DK1223966T3 - Anvendelse af GDNF til behandling af hornhindedefekter - Google Patents
Anvendelse af GDNF til behandling af hornhindedefekterInfo
- Publication number
- DK1223966T3 DK1223966T3 DK00983097T DK00983097T DK1223966T3 DK 1223966 T3 DK1223966 T3 DK 1223966T3 DK 00983097 T DK00983097 T DK 00983097T DK 00983097 T DK00983097 T DK 00983097T DK 1223966 T3 DK1223966 T3 DK 1223966T3
- Authority
- DK
- Denmark
- Prior art keywords
- gdnf
- agonist
- functionally active
- active derivative
- treat corneal
- Prior art date
Links
- 102000024452 GDNF Human genes 0.000 title abstract 4
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 title abstract 4
- 206010051559 Corneal defect Diseases 0.000 title 1
- 239000000556 agonist Substances 0.000 abstract 2
- 230000005714 functional activity Effects 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 210000004498 neuroglial cell Anatomy 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 230000029663 wound healing Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99121597 | 1999-10-29 | ||
| PCT/EP2000/010674 WO2001030375A2 (en) | 1999-10-29 | 2000-10-30 | Use of gdnf for treating corneal defects |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1223966T3 true DK1223966T3 (da) | 2003-08-18 |
Family
ID=8239299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK00983097T DK1223966T3 (da) | 1999-10-29 | 2000-10-30 | Anvendelse af GDNF til behandling af hornhindedefekter |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20030166537A1 (de) |
| EP (1) | EP1223966B1 (de) |
| JP (1) | JP2003512433A (de) |
| AT (1) | ATE238806T1 (de) |
| AU (1) | AU1997501A (de) |
| CA (1) | CA2385929A1 (de) |
| DE (1) | DE60002496T2 (de) |
| DK (1) | DK1223966T3 (de) |
| ES (1) | ES2198367T3 (de) |
| PT (1) | PT1223966E (de) |
| WO (1) | WO2001030375A2 (de) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7442370B2 (en) | 2001-02-01 | 2008-10-28 | Biogen Idec Ma Inc. | Polymer conjugates of mutated neublastin |
| US7276580B2 (en) * | 2001-03-12 | 2007-10-02 | Biogen Idec Ma Inc. | Neurotrophic factors |
| FR2825273B1 (fr) * | 2001-05-29 | 2006-11-24 | Oreal | Composition pour le traitement des signes cutanes du vieillissement |
| US20050222070A1 (en) * | 2002-05-29 | 2005-10-06 | Develogen Aktiengesellschaft Fuer Entwicklungsbiologische Forschung | Pancreas-specific proteins |
| JP4571776B2 (ja) * | 2002-11-05 | 2010-10-27 | Ｊｘ日鉱日石エネルギー株式会社 | 潤滑油組成物 |
| CA2864810A1 (en) | 2003-04-18 | 2004-11-04 | Biogen Idec Ma, Inc. | Polymer-conjugated glycosylated neublastin |
| AU2004245175C1 (en) | 2003-06-10 | 2010-03-18 | Biogen Ma Inc. | Improved secretion of neublastin |
| ATE435026T1 (de) | 2003-11-27 | 2009-07-15 | Develogen Ag | Verfahren zur prävention und behandlung von diabetes mit neurturin |
| EP1720564A1 (de) * | 2004-02-20 | 2006-11-15 | Rinat Neuroscience Corp. | Verfahren zur behandlung von fettsucht oder diabetes mit nt-4/5 |
| WO2005095450A2 (en) | 2004-03-30 | 2005-10-13 | Nsgene A/S | Therapeutic use of a growth factor, nsg33 |
| CN101123978B (zh) | 2004-08-19 | 2012-12-12 | 比奥根艾迪克Ma公司 | 神经胚素变体 |
| CA2577755C (en) * | 2004-08-19 | 2014-05-13 | Biogen Idec Ma Inc. | Neublastin variants |
| RU2008131939A (ru) * | 2006-02-02 | 2010-02-10 | Ринат Ньюросайенс Корп. (Us) | Способы лечения нежелательной потери веса или нарушений приема пищи агонистами trkb |
| EP1988920A1 (de) * | 2006-02-02 | 2008-11-12 | Rinat Neuroscience Corp. | Verfahren zur behandlung von fettsucht durch verabreichung eines trkb-antagonisten |
| TWI501774B (zh) * | 2006-02-27 | 2015-10-01 | Biogen Idec Inc | 神經性病症之治療 |
| US20100056440A1 (en) * | 2006-03-01 | 2010-03-04 | Biogen Idec Ma Inc. | Compositions and methods for administering gdnf ligand family proteins |
| US20080132451A1 (en) * | 2006-12-01 | 2008-06-05 | Alcon Manufacturing Ltd. | Modulation of polysialylated neural adhesion molecules (psa-ncam) as a regulator of ocular disease |
| AU2007337809A1 (en) * | 2006-12-20 | 2008-07-03 | Rinat Neuroscience Corporation | TrkB agonists for treating autoimmune disorders |
| ES2476253T3 (es) | 2007-05-01 | 2014-07-14 | Biogen Idec Ma Inc. | P�ptidos de neublastina para su uso en el aumento de la vascularizaci�n en tejido con flujo sanguíneo deteriorado |
| WO2009011892A2 (en) * | 2007-07-18 | 2009-01-22 | Boston Biomedical Research Institute | Use of suif proteins and heparan sulfate in gdnf-dependent neural innervation and protection |
| EP2205634A2 (de) * | 2007-08-08 | 2010-07-14 | Biogen Idec MA, Inc. | Anti-neublastin-antikörper und anwendungen davon |
| WO2010086828A2 (en) * | 2009-02-02 | 2010-08-05 | Rinat Neuroscience Corporation | Agonist anti-trkb monoclonal antibodies |
| JP5429865B2 (ja) * | 2009-09-15 | 2014-02-26 | 学校法人日本大学 | 生体外創傷治癒試験用用具または創傷作製方法 |
| US10376562B2 (en) | 2013-03-15 | 2019-08-13 | The Jackson Laboratory | Methods for promoting wound healing and hair growth comprising GDNF administration |
| JP6403217B2 (ja) | 2013-07-30 | 2018-10-10 | 京都府公立大学法人 | 角膜内皮ｅｃｍ治療薬 |
| CN107137698A (zh) * | 2017-03-03 | 2017-09-08 | 北京大学第三医院 | 一种包含gdnf的用于治疗角膜上皮损伤的药物组合物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5733875A (en) * | 1994-11-15 | 1998-03-31 | Amgen Inc. | Methods of using GDNF as a neuroprotective agent |
| US5837681A (en) * | 1996-02-23 | 1998-11-17 | Amgen Inc. | Method for treating sensorineural hearing loss using glial cell line-derived neurotrophic factor (GDNF) protein product |
| US5929041A (en) * | 1996-02-23 | 1999-07-27 | Amgen Inc. | Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product |
| WO1997049798A1 (en) * | 1996-06-27 | 1997-12-31 | University Of Helsinki | Glial cell line-derived neurotrophic factor regulation of ureteric budding and growth, and of enteric innervation |
| US6391312B1 (en) * | 1997-01-23 | 2002-05-21 | Sumitomo Pharmaceuticals Co., Limited | Remedies for diabetes |
-
2000
- 2000-10-30 PT PT00983097T patent/PT1223966E/pt unknown
- 2000-10-30 DE DE60002496T patent/DE60002496T2/de not_active Expired - Fee Related
- 2000-10-30 AT AT00983097T patent/ATE238806T1/de not_active IP Right Cessation
- 2000-10-30 EP EP00983097A patent/EP1223966B1/de not_active Expired - Lifetime
- 2000-10-30 AU AU19975/01A patent/AU1997501A/en not_active Abandoned
- 2000-10-30 WO PCT/EP2000/010674 patent/WO2001030375A2/en active IP Right Grant
- 2000-10-30 JP JP2001532792A patent/JP2003512433A/ja active Pending
- 2000-10-30 ES ES00983097T patent/ES2198367T3/es not_active Expired - Lifetime
- 2000-10-30 DK DK00983097T patent/DK1223966T3/da active
- 2000-10-30 CA CA002385929A patent/CA2385929A1/en not_active Abandoned
-
2002
- 2002-04-24 US US10/132,069 patent/US20030166537A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PT1223966E (pt) | 2003-09-30 |
| CA2385929A1 (en) | 2001-05-03 |
| EP1223966A2 (de) | 2002-07-24 |
| WO2001030375A2 (en) | 2001-05-03 |
| DE60002496T2 (de) | 2004-03-25 |
| US20030166537A1 (en) | 2003-09-04 |
| EP1223966B1 (de) | 2003-05-02 |
| ES2198367T3 (es) | 2004-02-01 |
| WO2001030375A3 (en) | 2002-03-21 |
| ATE238806T1 (de) | 2003-05-15 |
| DE60002496D1 (de) | 2003-06-05 |
| AU1997501A (en) | 2001-05-08 |
| JP2003512433A (ja) | 2003-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1223966T3 (da) | Anvendelse af GDNF til behandling af hornhindedefekter | |
| DE50213524D1 (de) | Kationische sterolderivate, ph-sensitive liposomen diese umfassend und verfahren zur wirkstoffbeladung von liposomen | |
| YU75903A (sh) | Tiohidantoini i njihovo korišćenje u lečenju dijabetisa | |
| ATE388951T1 (de) | Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes | |
| YU40701A (sh) | Piperidini kao modulatori ccr5 | |
| BR0110703A (pt) | Amida, composição farmacêutica que compreende um composto, compostos, utilização de compostos, processos para o tratamento profilático ou terapêutico de diabetes do tipo ii e para a preparação desses compostos | |
| MXPA02012272A (es) | Compuestos heterociclicos que son inhibidores de la enzima dipeptidilpeptidasa-iv. | |
| DE602005020165D1 (de) | Verfahren zur herstellung von l-arginin, l-ornithin oder l-citrullin | |
| BR0312563A (pt) | Comprimido de lasofoxifeno e seu revestimento | |
| PT1206467E (pt) | Derivados n-heterociclicos como inibidores de nos | |
| BR0007589A (pt) | Inibidores da proliferação de células | |
| ATE251448T1 (de) | Polyol/öl-suspensionen zur verzörgerten freisetzung von proteinen | |
| FI963294A0 (fi) | Naftyyliamidit keskushermostoaineina | |
| DE60211539D1 (de) | Imidazopyridinderivate zur verwendung bei der behandlung von herpes-vireninfektion | |
| DE60024100D1 (de) | Von dem syndrom der weissen flecken virus abgeleitete proteine und deren verwendungen | |
| ATE424894T1 (de) | Zusammensetzung zur förderung des haarwachstums | |
| HUP9902640A2 (hu) | Gliasejtvonal-eredetű neurotróf faktor receptor | |
| ATE211391T1 (de) | Verwendung von hmg proteinen zur herstellung von arzneimitteln mit zytotoxischer wirkung | |
| MXPA04003526A (es) | Composicion y metodo para el tratamiento de la diabetes. | |
| PT1165544E (pt) | 1,4-di-hidroindeno¬1,2-c|pirazoles substituidos como inibidores de tirosina-quinase | |
| RU2001131354A (ru) | Стабильная композиция, включающая фактор роста эпидермиса в качестве активного ингредиента | |
| ATE290857T1 (de) | Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen | |
| DK0935652T3 (da) | Keratinocyt vækstfaktor-2 produkter | |
| EP1801232A4 (de) | Verfahren zum screening eines transmembranenzymhemmstoffs | |
| JO2724B1 (en) | 3-Alternative-5 -6-Amino Alkyl Indole-2-Carboxyl Acid Amide and Related Isotopes as Casein Kinase Inhibitors |